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Abstract 
Enrollment of patients in sickle cell intervention trials has been challenging due to 
difficulty obtaining consent from a legal guardian and lack of collaboration between 
emergency medicine and hematology. We utilized education and pre-consent in a 
pediatric multi-site sickle cell intervention trial to overcome these challenges. Overall, 
48 patients were enrolled after being pre-consented. Variable Institutional Review 
Board policies related to pre-consent validity and its allowable duration decreased 
the advantages of pre-consent at some sites. The utility of pre-consent for future 
intervention trials largely depends on local IRB policies. Pre-education may also 
benefit the consent process, regardless of site differences. 
 
Introduction 
Intervention trials in children with sickle cell disease (SCD) hospitalized for acute 
pain are frequently hindered by several barriers to enrollment. These barriers have 
resulted in the early termination of studies due to poor enrollment, [1-3] potentially 
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particularly at night and during weekends, due to limited research staff availability. 
[2,3] Additionally, waiting  for legal authorized representatives (LARs) to be available 
on the inpatient floor instead of completing consent in the emergency department 
(ED) can delay or preclude consent. [4, 5] Another barrier is a lack of trust between 
families and providers [3, 6-8], which is accentuated by the lack of a relationship 
between emergency medicine physicians and families. Minority families in particular 
may have preexisting mistrust of research that can only be mitigated by a provider 
with whom the family shares a strong relationship. [9, 10] Stress associated with the 
ED environment can be tense and upsetting for families, [11] who may be unwilling 
or unable to focus on research studies. [12] Finally, obtaining assent in children with 
SCD after they received opioids may be problematic due to decreased levels of 
consciousness and attention. [13, 14] 
 
Pre-consent—informed consent given in advance of an eligible ED visit—has been 
suggested as a way to overcome these barriers. [6, 15, 16] Children with SCD and 
other chronic conditions are seen, accompanied by an LAR, at regular intervals in 
the outpatient setting. Thus, clinic visits represent an opportunity to educate families 
about an ongoing study in a controlled environment, outside of the stressful ED. Pre-
consent may then facilitate enrollment for inpatient clinical trials. We incorporated a 
pre-consent process in a multi-site, randomized clinical trial conducted within the 
Pediatric Emergency Care Applied Research Network (PECARN). In the Intravenous 
Magnesium for Sickle Cell Vasoocclusive Crisis (MAGiC) trial, [17, 18] the pre-
consent process was jointly conducted by research staff from the ED and 
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SCD and their families. Here, we describe our pre-consent process, the benefits and 
challenges of pre-consent in the MAGiC study, and suggest key items to consider 
when deciding whether to pre-consent in future intervention trials.  IRB approval was 
obtained as part of the parent trial.  
 
Methods 
In the MAGiC study, four of eight enrolling sites adopted a pre-consent process. The 
other four sites cited past experience, an understanding of the limits of pre-consent 
gained from participating sites and resource limitations as factors for declining to 
institute a pre-consent process. 
 
The pre-consent process was similar across the sites. Sites worked with their 
Hematology clinics to identify patients likely to be eligible based on 
inclusion/exclusion criteria (e.g. HbSS or HbSβ0 genotype, not on chronic transfusion 
therapy, no history of stroke) or frequency of recent hospitalizations. The pre-
consent process was identical to the standard consent with the exception that the 
pre-consent introduction was given by the clinic hematologist as opposed to the 
enrolling research staff in the ED. In both scenarios, the introduction was followed by 
a full, informed-consent discussion and signing of the consent document. When a 
pre-consented child returned for an eligible ED visit, willingness to participate was 
verbally confirmed and key study procedures reviewed. All signed consents were 
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In total, all 8 sites randomized 208 patients into the trial. [8] Among the 4 pre-
consenting sites, 177 (77%) of all approached patients were first approached for 
consent in the ED while 53 (23%) were previously pre-consented (Table I). Of the 
177 patients who were not pre-consented, 72 (41%) were randomized, compared to 
48 (91%) of the pre-consented patients (p < .001). 
 
Altogether, sites pre-consented 134 patients: 48 (36%) were subsequently 
approached and randomized, 5 (4%) were approached but did not wish to be 
randomized at that time and the remaining 81 (60%) never had a qualifying ED visit 
during the study period. Pre-consented patients comprised 23% of all randomized 
patients and 40% (48/120) of randomized patients among the pre-consenting sites.  
Analysis by time of day revealed that , 33% (16/48) of the pre-consented patients 
presented between 10pm and 6am compared to 38% (27/72) of patients  who were 
not pre-consented (p = .641). The percentage of pre-consented patients who were 
subsequently enrolled ranged by site from 24% to 56%.  
 
A major finding reported by site research staff was IRB variability in the duration of 
the validity of the signed pre-consent document. At the two sites with the most 
stringent IRB consent requirements, signed consents expired at the annual 
continuing review, even if the consent had been signed only one month before. This 
expiration forced these sites to re-consent if not enrolled prior to the date of the 
continuing review. This made pre-consenting in the last quarter of the year unlikely to 
yield successful pre-consent. Additionally, one of these sites’ IRBs invalidated all 
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the consent form, while the other site invalidated all pre-consents if any part of the 
consent form changed. IRBs at the two remaining sites considered signed consents 
to be valid until the subject reached the age of majority as long as no significant 
changes occurred in the risks/benefits or study procedures. Finally, there were 
institutional differences related to the need for LAR presence at enrollment after 
when pre-consent. At one site, the LAR needed to be in the ED to sign an additional, 
shorter consent form prior to randomization (although no patients were actually 
unable to enroll due to this restriction), while the other three sites’ enrollment was 
allowed  without an LAR. 
 
Among the two sites with the greatest number of pre-consented subjects, 18/70 
(25.7%) patients at the site with the more stringent IRB were randomized compared 
to 14/32 (43.8%) of patients at the less stringent site (p = .069). Both sites had a 
similar proportion of their pre-consented patients randomized on nights/weekends. 
The number of pre-consented patients across sites reflected the size of the sickle 
cell program at each site. 
 
Discussion 
In a multi-site, sickle cell intervention trial, pre-consent in the clinic setting provided a 
means by which to address several barriers to enrollment in the ED. In this study, 
pre-consent facilitated enrollment in the absence of an LAR; highlighted to families 
the collaboration between ED and Hematology, and provided a comfortable, less 
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When comparing randomization rates between those pre-consented and not, the 
proportion of pre-consented patients who were randomized was more than double 
that of those who were not pre-consented, with more than 90% of approached pre-
consented subjects being randomized into the trial. By comparison, a recently 
completed treatment trial of acute SCD pain crisis by Telen MJ et al., randomized 76 
patients during 31 months of enrollment across 22 sites, averaging 0.11 patients per 
site per month. [19] The MAGiC study randomized 208 patients during 36 months 
across 8 sites, averaging 0.73 patients per site per month. 
 
Approaching families at clinic visits as part of the MAGiC pre-consent process was 
also a form of pre-education. The study was introduced by the hematologist and 
consent discussions occurred with the research staff. Even if consent was not 
obtained, families were educated about the study and general research concerns 
may have been eliminated. While pre-consent is a longer and more thorough 
process than pre-education, pre-consent may not be worthwhile at all sites.  
 
Local IRB policies greatly influenced the degree to which sites were able to benefit 
from the pre-consent process. Although not statistically significant, the difference in 
randomization rates between the two sites with the most stringent and most flexible 
IRB consent policies highlights the importance of the IRB when evaluating the 
potential effectiveness of pre-consent. 
 
We believe that pre-consent is a valuable strategy to address barriers to enrollment 
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understanding of the regulatory requirements adopted by their local IRBs to 
determine whether that particular site would benefit from a pre-consent process.    
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Table I. Number of subjects approached and randomized by site. 
Site Consent type Approached,* n 
Randomized,  
n (% of approached) 
Site A 
Standard 79 25 (31.6) 
Pre-consent 22 18 (81.8) 
Site B 
Standard 35 20 (57.1) 
Pre-consent 15 14 (93.3) 
Site C 
Standard 42 16 (38.1) 
Pre-consent 7 7 (100.0) 
Site D 
Standard 21 11 (52.4) 
Pre-consent 9 9 (100.0) 
Site E Standard 52 28 (53.8) 




This article is protected by copyright. All rights reserved. 
 
Site G Standard 49 23 (46.9) 
Site H Standard 19 13 (68.4) 
 
*Approached at an eligible ED visit (additional subjects approached for pre-consent 
at each of the four pre-consenting sites are not included because these subjects 
never had a subsequent eligible visit). 
 
 
 
 
 
 
 
 
 
 
 
